UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +10.0% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 159 | +4 | 28.21M | $15.29B | +8 | −3 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | — |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | — | — |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | — |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | — | — |
| Q2 2024 | 14 | — | 8.17M | $2.60B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 3.17M | -3.5% | $1.14B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 2.16M | -0.9% | $772.38M | 1.2% | ▼ Trim | 2 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 1.09M | +4.3% | $391.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passief) | 1.09M | +4.3% | $391.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 967.73K | +34.5% | $346.79M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 967.73K | +34.5% | $346.79M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 967.73K | +34.5% | $346.79M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 967.73K | +34.5% | $346.79M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 641.60K | +46.3% | $229.92M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 18 | Norges Bank ✦ (passief) | 423.63K | +988.2% | $151.81M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | T. Rowe Price ✦ | 344.53K | +46.7% | $123.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 344.53K | +46.7% | $123.46M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 61.76K | +384.3% | $22.13M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 52.06K | +9.4% | $18.65M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 51.55K | +22.7% | $18.47M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | D. E. Shaw & Co. ✦ | 51.55K | +22.7% | $18.47M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 25 | Marshall Wace ✦ | 12.71K | -36.8% | $4.55M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | Millennium Management ✦ | 9.05K | -91.2% | $3.24M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 27 | Fisher Asset Management ✦ | 6.30K | +22.3% | $2.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 28 | Two Sigma Investments ✦ | 1.72K | -9.4% | $616,720 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 218.70K aandelen, $129,684 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 1.32K aand · $675,421
Officer, Director · 3.59K aand · $1.84M
Officer, Director · 224 aand · $114,108
Officer, Director · 3.06K aand · $1.56M
Officer, Director · 1.30K aand · $669,921
Officer, Director · 773 aand · $399,695
Officer, Director · 235 aand · $123,474
Officer, Director · 455 aand · $238,247
Officer, Director · 669 aand · $349,411
Officer, Director · 271 aand · $139,254
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie